BioAtla : Presentation_Needham_FINAL91 - Read-Only.pdf

Important Notices & Disclaimers

This presentation (the "Presentation") by BioAtla, Inc. ("we", "us", "our", "BioAtla", or the "Company") contains "forward-looking statements" within the meaning of the Private

Securities Litigation Reform Act of 1995 relating to our business, operations and financial conditions, including but not limited to current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, results of clinical trials and other future conditions. Words such as, but not limited to, "anticipate", "believe", "could", "estimate", "expect", "intend", "may", "plan", "potential", "predict", "project", "should", "will", "would" or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes, identify forward-looking statements.

These forward-looking statements reflect management's beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this Presentation and are subject to risks and uncertainties, including those described in the Company's filings with the SEC, including but not limited to the Company's latest Annual Report on Form 10-K. Moreover, the Company operates in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for management to predict all risks, nor can the Company assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The Company qualifies all the forward-looking statements in this Presentation by these cautionary statements. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Statements contained herein are made as of the date of this Presentation unless stated otherwise, and this Presentation shall not under any circumstances create an implication that the information contained herein is correct as of any time after such date or that the information will be updated or revisited to reflect information that subsequently becomes available or changes occurring after that date hereof.

Certain information contained in this Presentation relates to or is based on statistical and other industry and market data obtained from independent industry publications and research, surveys and studies conducted by independent third parties as well as the Company's own estimates of the prevalence of certain diseases and conditions. The market data used in this Presentation involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. The Company's estimates of the patient population with the potential to benefit from treatment with any product candidates the Company may develop include several key assumptions based on its industry knowledge, industry publications and third-party research, which may be based on a small sample size and may fail to accurately reflect the addressable patient population. While the Company believes that its internal assumptions are reasonable, no independent source has verified such assumptions.

This Presentation may contain trademarks, trade names, or service marks belonging to other entities. The Company does not intend the use or display of other parties' trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of, or by these other parties.

None of the Company or any of its directors, officers, employees, contractors, agents, consultants, advisors or other representatives makes any representation or warranty, express or implied, as to the accuracy or completeness of the information contained in this Presentation.

BioAtla© is a clinical-stage biotech company focused on transforming cancer therapy with Conditionally Active Biologics (CABs)

THE COMPANY

TECHNOLOGY

Proprietary CAB technology that conditionally and reversibly bind to cancer cells, but not to normal cells, enabling increased antibody potency and reduced toxicity

Strong intellectual property rights: - 621 patents (360 issued, 9 allowed, and 252 pending)

CLINICAL & TEAM

Broad clinical and development pipeline with two 1st-in-class P2 CAB-ADCs for multiple indications and CAB-CTLA-4 initiated P1 clinical studies

Over 60 employees with exceptional experience in innovative research and clinical development

FINANCE & INFRASTRUCTURE

Building on successful 2020 IPO, over $290MM in gross proceeds, (including $75.0 MM raised 9/21). $245MM cash at EOY 2021 funds operations into 2024

Headquartered in San Diego in a ~43,000 square foot office and lab facility with a contract lab in Beijing

Tumor cell acidity enables selective, reversible CAB binding via the novel physiological-occurring PaCSTM* molecule mechanism

THE TECHNOLOGY

In Alkaline Healthy Cell Membranes…

In normal tissue (+) charged amino acid residues shield protein targets from drug attack by binding to (-) charged PaCSTM molecules.

2The Warburg Effect

Prodrugs and masked antibodies require activation. Once activated, they cannot become inactive circulating from diseased to normal tissues. Chang, H.W., Frey, G., Liu, H., Xing, C., Steinman, L, Boyle, B.J., & Short, J.M. (2021) PNAS 118(9): 1-10, Suppl. 1-19..

*PaCS = Protein-associated Chemical SwitchesTM **Glycolysis underpins the success of PET scanning

In Acidic Cancer Cell Membranes

In the acidic TME the PaCS molecules are neutralized by H+, exposing targets to drug attack. With no requirement for activation.

¥2nd Gen ADC features complementing CAB Technology:

• 1. conjugation without sequence modification of antibody at DAR

  4 and higher

• 2. high serum stability and high solubility with sugar-based linker

• 3. cleavage only in the lysosome with potential to reduce risk of neutropenia and neuropathy